Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The MDM‐2 (murine double minute 2) gene codes for a cellular protein that can bind to the p53 tumor suppressor gene product, thereby functioning as a negative regulator of p53. In order to define the role of the MDM‐2 gene in the pathogenesis of human acute myeloid leukemia, the expression and the sequence of the MDM‐2 gene were examined in samples of bone marrow and/or peripheral mononuclear cells of 38 patients by using immunostaining, polymerase chain reaction (PCR), single strand conformation polymorphism, and sequencing. Immunohistochemical staining detected a weak accumulation of the MDM‐2 protein in AML patients of FAB classification M4 and M5. RT‐PCR analysis revealed a heterogeneous expression pattern of MDM‐2 mRNA in AML samples of different FAB classification. An increased level of MDM‐2 mRNA expression was observed in 17 of 38 AML patients when compared to normal controls. No structural changes in a 488 bp region extending from nucleotide 890 to 1378 of the MDM‐2 cDNA were detected using RT‐SSCP and sequence analysis. In addition, heterogeneous expression of p53 transcripts was found with the highest p53 mRNA levels in AML M4 and M5. Interestingly, there seems to be a correlation between the relative ratios of p53 and MDM‐2 mRNA levels in AML M4 and M5: in 15 of 23 cases high p53 mRNA expression was directly associated with high levels of MDM‐2 transcripts. An exclusively intranuclear p53 immunostaining pattern was found in 10 of 16 (58%) AML FAB M4 and M5, whereas the remaining AML samples tested were negative for p53 (0/10). Using RT‐SSCP analysis and direct sequencing of the RT‐PCR amplification products of p53 exon 5–8, we observed that only 1 of 38 AML patients showed a point mutation in the p53 gene. This missense mutation occurred in the evolutionary highly conserved region of p53 at codon 255 (Ile to Phe). These data indicated that structural alterations of the p53 gene do not play an important role in the initiation and progression of AML. However, abrogation of p53 tumor suppressor function due to MDM‐2 overexpression may be an alternative molecular mechanism by which a subset of AMLs may escape from p53‐regulated growth control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719 · cited 1×
“In the present study, we have screened a large series of peripheral blood mononuclear cells (PBMNC) and bone marrow (BM) from patients with AML for the structure and expression of p53 exon 5 through 8 as well as the MDM-2 gene by using immunohistochemistry, PCR (35) and PCR-SSCP (36, 37) methods in combination with th…”
MethodThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311
Analysis of glioma cell lines for amplification and overexpression of MDM2
He, J., Reifenberger, G., Liu, L., Collins, V. P., & James, C. D. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870110205 · Cited by 56
Cited by
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
Kojima, K., Konopleva, M., Samudio, I. J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407
Function of the c-Myc Oncogenic Transcription Factor
Dang, C. V., Resar, L. M. S., Emison, E., Kim, S., Li, Q., Prescott, J. E., Wonsey, D., & Zeller, K. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4686 · Cited by 379
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
Zhang, W., Konopleva, M., Burks, J. K., Dywer, K. C., Schober, W. D., Yang, J.-Y., McQueen, T. J., Hung, M.-C., & Andreeff, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0878 · Cited by 70
Metadata
- Authors
- Seliger, B., Papadileris, S., Vogel, D., Hess, G., Brendel, C., Störkel, S., örtel, J., Kolbe, K., Huber, C., Huhn, D., & Neubauer, A.
- Venue
- European Journal of Haematology
- Publisher
- Wiley
- Published
- 1996-09
- Volume
- 57
- Issue
- 3
- Pages
- 230-240
- ISSN
- 0902-4441 (ISSN-L)
- 1600-0609
- OpenAlex
- W1990675489
- Cited by
- 55
- References
- 7
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia. https://app.cochat.ai/papers/10.1111/j.1600-0609.1996.tb01369.x
- The paper
- Seliger, B., Papadileris, S., Vogel, D., Hess, G., Brendel, C., Störkel, S., örtel, J., Kolbe, K., Huber, C., Huhn, D., & Neubauer, A. (1996). Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia. European Journal of Haematology. https://doi.org/10.1111/j.1600-0609.1996.tb01369.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.